CoChat
Sign Up
Cited by 28Dermatology and Skin DiseasesContact Dermatitis and AllergiesAsthma and respiratory diseases

The pathology of type 2 inflammation-associated itch in atopic dermatitis

Open access
Moniaga, Catharina Sagita, Tominaga, Mitsutoshi, Takamori, Kenji·2021·Diagnostics
DOI 10.3390/diagnostics11112090PMC PMC8618746
Open this paper in CoChat — free accountOpen PDF

Abstract

Accumulated evidence on type 2 inflammation-associated itch in atopic dermatitis has recently been reported. Crosstalk between the immune and nervous systems (neuroimmune interactions) is prominent in atopic dermatitis research, particularly regarding itch and inflammation. A comprehensive understanding of bidirectional neuroimmune interactions will provide insights into the pathogenesis of itch and its treatment. There is currently no agreed cure for itch in atopic dermatitis; however, increasing numbers of novel and targeted biologic agents have potential for its management and are in the advanced stages of clinical trials. In this review, we summarize and discuss advances in our understanding of type 2 inflammation-associated itch and implications for its management and treatment in patients with atopic dermatitis.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/diagnostics11112090

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • TSLP induces the expression of the major class I and II histocompatibility complex and costimulatory molecules in dendritic cells, which produce Th2 cell-attractive chemokines such as TARC and CCL22 and induce Th2 differentiation through enhanced expression of OX40 L.

    “Furthermore, TSLP induces the expression of the major class I and II histocompatibility complex and in costimulatory molecules in dendritic cells, which produce Th2 cell-attractive chemokines such as TARC and CCL22 and induce Th2 differentiation through the enhanced expression of the costimulatory molecule OX40 L in the dendritic cell.”

    From Update on the pathogenesis of atopic dermatitis. (2024) · cites this paper as [7]

    Split into 2 atoms — 0 confirmed, 2 partially supported, 0 disputed, 0 misattributed, 0 unverifiable. Expand the claim to see per-atom verdicts.

    Experimental — accuracy not yet measured

  • Various hematopoietic cells and sensory neurons express the TSLP Receptor (TSLPR).

    “Various hematopoietic cells and sensory neurons express the TSLP Receptor (TSLPR).”

    From Update on the pathogenesis of atopic dermatitis. (2024) · cites this paper as [7]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 126 · Cited by 28

Research works printed but not linked: 114

  1. [1]Puar N. Chovatiya R. Paller A.S. New treatments in atopic dermatitis Ann. Allergy Asthma Immunol. 2021 126 21 31 10.1016/j.anai.2020.08.016 32818591 · DOI
  2. [2]Czarnowicki T. He H. Krueger J.G. Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics J. Allergy Clin. Immunol. 2019 143 1 11 10.1016/j.jaci.2018.10.032 30612663 · DOI
  3. [3]Leung D.Y. Guttman-Yassky E. Assessing the current treatment of atopic dermatitis: Unmet needs J. Allergy Clin. Immunol. 2017 139 S47 S48 10.1016/j.jaci.2017.01.010 28390476 · DOI
  4. [4]Langan S.M. Irvine A.D. Weidinger S. Atopic dermatitis Lancet 2020 396 345 360 10.1016/S0140-6736(20)31286-1 32738956 · DOI
  5. [5]Wong L.S. Wu T. Lee C.H. Inflammatory and Noninflammatory Itch: Implications in Pathophysiology-Directed Treatments Int. J. Mol. Sci. 2017 18 1485 10.3390/ijms18071485 PMC5535975 28698528 · DOI
  6. [6]Hawro T. Przybylowicz K. Spindler M. Hawro M. Stec M. Altrichter S. Weller K. Magerl M. Reidel U. Alarbeed E. The characteristics and impact of pruritus in adult dermatology patients: A prospective, cross-sectional study J. Am. Acad. Dermatol. 2021 84 691 700 10.1016/j.jaad.2020.08.035 32798581 · DOI
  7. [7]Nattkemper L.A. Tey H.L. Valdes-Rodriguez R. Lee H. Mollanazar N.K. Albornoz C. Sanders K.M. Yosipovitch G. The Genetics of Chronic Itch: Gene Expression in the Skin of Patients with Atopic Dermatitis and Psoriasis with Severe Itch J. Investig. Dermatol. 2018 138 1311 1317 10.1016/j.jid.2017.12.029 29317264 · DOI
  8. [8]Bieber T. D’Erme A.M. Akdis C.A. Traidl-Hoffmann C. Lauener R. Schappi G. Schmid-Grendelmeier P. Clinical phenotypes and endophenotypes of atopic dermatitis: Where are we, and where should we go? J. Allergy Clin. Immunol. 2017 139 S58 S64 10.1016/j.jaci.2017.01.008 28390478 · DOI
  9. [10]Silverberg J.I. Gelfand J.M. Margolis D.J. Boguniewicz M. Fonacier L. Grayson M.H. Simpson E.L. Ong P.Y. Chiesa Fuxench Z.C. Patient burden and quality of life in atopic dermatitis in US adults: A population-based cross-sectional study Ann. Allergy Asthma Immunol. 2018 121 340 347 10.1016/j.anai.2018.07.006 30025911 · DOI
  10. [11]Halvorsen J.A. Lien L. Dalgard F. Bjertness E. Stern R.S. Suicidal ideation, mental health problems, and social function in adolescents with eczema: A population-based study J. Investig. Dermatol. 2014 134 1847 1854 10.1038/jid.2014.70 24496238 · DOI
  11. [12]Xerfan E.M.S. Tomimori J. Andersen M.L. Tufik S. Facina A.S. Sleep disturbance and atopic dermatitis: A bidirectional relationship? Med. Hypotheses 2020 140 109637 10.1016/j.mehy.2020.109637 32097844 · DOI
  12. [13]Chang Y.S. Chiang B.L. Mechanism of Sleep Disturbance in Children with Atopic Dermatitis and the Role of the Circadian Rhythm and Melatonin Int. J. Mol. Sci. 2016 17 462 10.3390/ijms17040462 27043528 PMC4848918 · DOI
  13. [14]Ariens L.F.M. van Nimwegen K.J.M. Shams M. de Bruin D.T. van der Schaft J. van Os-Medendorp H. De Bruin-Weller M. Economic Burden of Adult Patients with Moderate to Severe Atopic Dermatitis Indicated for Systemic Treatment Acta Derm.-Venereol. 2019 99 762 768 10.2340/00015555-3212 31073619 · DOI · Paper page
  14. [15]Tsai T.F. Rajagopalan M. Chu C.Y. Encarnacion L. Gerber R.A. Santos-Estrella P. Llamado L.J.Q. Tallman A.M. Burden of atopic dermatitis in Asia J. Dermatol. 2019 46 825 834 10.1111/1346-8138.15048 31436343 · DOI
  15. [16]Luk K.M. Shaw F.M. Zhang C. Culler S.D. Chen S.C. The Annual Direct and Indirect Health Care Costs for Patients with Chronic Pruritus and their Determining Factors J. Investig. Dermatol. 2020 140 699 701.e5 10.1016/j.jid.2019.07.711 31465742 · DOI
  16. [17]Lee B.W. Detzel P.R. Treatment of childhood atopic dermatitis and economic burden of illness in Asia Pacific countries Ann. Nutr. Metab. 2015 66 (Suppl. 1) 18 24 10.1159/000370221 25925337 · DOI
  17. [18]Olsson M. Bajpai R. Wee L.W.Y. Yew Y.W. Koh M.J.A. Thng S. Car J. Jarbrink K. The cost of childhood atopic dermatitis in a multi-ethnic Asian population: A cost-of-illness study Br. J. Dermatol. 2020 182 1245 1252 10.1111/bjd.18442 31420964 · DOI
  18. [19]Matsunaga K. Katoh N. Fujieda S. Izuhara K. Oishi K. Dupilumab: Basic aspects and applications to allergic diseases Allergol. Int. Off. J. Jpn. Soc. Allergol. 2020 69 187 196 10.1016/j.alit.2020.01.002 32007360 · DOI
  19. [20]Gandhi N.A. Bennett B.L. Graham N.M. Pirozzi G. Stahl N. Yancopoulos G.D. Targeting key proximal drivers of type 2 inflammation in disease Nat. Rev. Drug Discov. 2016 15 35 50 10.1038/nrd4624 26471366 · DOI · Paper page
  20. [21]Tojima I. Matsumoto K. Kikuoka H. Hara S. Yamamoto S. Shimizu S. Kouzaki H. Shimizu T. Evidence for the induction of Th2 inflammation by group 2 innate lymphoid cells in response to prostaglandin D2 and cysteinyl leukotrienes in allergic rhinitis Allergy 2019 74 2417 2426 10.1111/all.13974 31267527 · DOI
  21. [22]Li S. Morita H. Sokolowska M. Tan G. Boonpiyathad T. Opitz L. Orimo K. Archer S.K. Jansen K. Tang M.L.K. Gene expression signatures of circulating human type 1, 2, and 3 innate lymphoid cells J. Allergy Clin. Immunol. 2019 143 2321 2325 10.1016/j.jaci.2019.01.047 30825467 · DOI
  22. [23]Toki S. Goleniewska K. Zhang J. Zhou W. Newcomb D.C. Zhou B. Kita H. Boyd K.L. Peebles R.S. Jr. TSLP and IL-33 reciprocally promote each other’s lung protein expression and ILC2 receptor expression to enhance innate type-2 airway inflammation Allergy 2020 75 1606 1617 10.1111/all.14196 31975538 PMC7354889 · DOI
  23. [24]Xiong Y. Cui X. Li W. Lv J. Du L. Mi W. Li H. Chen Z. Leng Q. Zhou H. BLT1 signaling in epithelial cells mediates allergic sensitization via promotion of IL-33 production Allergy 2019 74 495 506 10.1111/all.13656 30390302 · DOI
  24. [25]Ro M. Lee A.J. Kim J.H. 5-/12-Lipoxygenase-linked cascade contributes to the IL-33-induced synthesis of IL-13 in mast cells, thus promoting asthma development Allergy 2018 73 350 360 10.1111/all.13294 28857185 · DOI
  25. [26]Pasha M.A. Patel G. Hopp R. Yang Q. Role of innate lymphoid cells in allergic diseases Allergy Asthma Proc. 2019 40 138 145 10.2500/aap.2019.40.4217 31018888 PMC6500789 · DOI
  26. [27]von Moltke J. O’Leary C.E. Barrett N.A. Kanaoka Y. Austen K.F. Locksley R.M. Leukotrienes provide an NFAT-dependent signal that synergizes with IL-33 to activate ILC2s J. Exp. Med. 2017 214 27 37 10.1084/jem.20161274 28011865 PMC5206504 · DOI
  27. [28]Neill D.R. Wong S.H. Bellosi A. Flynn R.J. Daly M. Langford T.K. Bucks C. Kane C.M. Fallon P.G. Pannell R. Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity Nature 2010 464 1367 1370 10.1038/nature08900 20200518 PMC2862165 · DOI
  28. [29]Kim B.S. Siracusa M.C. Saenz S.A. Noti M. Monticelli L.A. Sonnenberg G.F. Hepworth M.R. Van Voorhees A.S. Comeau M.R. Artis D. TSLP elicits IL-33-independent innate lymphoid cell responses to promote skin inflammation Sci. Transl. Med. 2013 5 170ra116 10.1126/scitranslmed.3005374 PMC3637661 23363980 · DOI
  29. [30]Salimi M. Barlow J.L. Saunders S.P. Xue L. Gutowska-Owsiak D. Wang X. Huang L.C. Johnson D. Scanlon S.T. McKenzie A.N. A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis J. Exp. Med. 2013 210 2939 2950 10.1084/jem.20130351 24323357 PMC3865470 · DOI
  30. [31]Imai Y. Interleukin-33 in atopic dermatitis J. Dermatol. Sci. 2019 96 2 7 10.1016/j.jdermsci.2019.08.006 31455506 · DOI
  31. [32]Suarez-Farinas M. Dhingra N. Gittler J. Shemer A. Cardinale I. de Guzman Strong C. Krueger J.G. Guttman-Yassky E. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis J. Allergy Clin. Immunol. 2013 132 361 370 10.1016/j.jaci.2013.04.046 23777851 PMC3991240 · DOI · Paper page
  32. [33]Gittler J.K. Shemer A. Suarez-Farinas M. Fuentes-Duculan J. Gulewicz K.J. Wang C.Q. Mitsui H. Cardinale I. de Guzman Strong C. Krueger J.G. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis J. Allergy Clin. Immunol. 2012 130 1344 1354 10.1016/j.jaci.2012.07.012 22951056 PMC3991245 · DOI · Paper page
  33. [35]Suarez-Farinas M. Tintle S.J. Shemer A. Chiricozzi A. Nograles K. Cardinale I. Duan S. Bowcock A.M. Krueger J.G. Guttman-Yassky E. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities J. Allergy Clin. Immunol. 2011 127 954 964.e4 10.1016/j.jaci.2010.12.1124 21388663 PMC3128983 · DOI
  34. [36]Pacor M.L. Di Lorenzo G. Martinelli N. Mansueto P. Rini G.B. Corrocher R. Comparing tacrolimus ointment and oral cyclosporine in adult patients affected by atopic dermatitis: A randomized study Clin. Exp. Allergy J. Br. Soc. Allergy Clin. Immunol. 2004 34 639 645 10.1111/j.1365-2222.2004.1907.x 15080819 · DOI
  35. [37]Hijnen D. De Bruin-Weller M. Oosting B. Lebre C. De Jong E. Bruijnzeel-Koomen C. Knol E. Serum thymus and activation-regulated chemokine (TARC) and cutaneous T cell-attracting chemokine (CTACK) levels in allergic diseases: TARC and CTACK are disease-specific markers for atopic dermatitis J. Allergy Clin. Immunol. 2004 113 334 340 10.1016/j.jaci.2003.12.007 14767451 · DOI
  36. [38]Jahnz-Rozyk K. Targowski T. Paluchowska E. Owczarek W. Kucharczyk A. Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis Allergy 2005 60 685 688 10.1111/j.1398-9995.2005.00774.x 15813816 · DOI
  37. [39]Meng Y. Wang C. Zhang L. Recent developments and highlights in allergic rhinitis Allergy 2019 74 2320 2328 10.1111/all.14067 31571226 · DOI
  38. [40]Sugita K. Altunbulakli C. Morita H. Sugita A. Kubo T. Kimura R. Goto H. Yamamoto O. Ruckert B. Akdis M. Human type 2 innate lymphoid cells disrupt skin keratinocyte tight junction barrier by IL-13 Allergy 2019 74 2534 2537 10.1111/all.13935 31166013 · DOI
  39. [41]Sugita K. Steer C.A. Martinez-Gonzalez I. Altunbulakli C. Morita H. Castro-Giner F. Kubo T. Wawrzyniak P. Ruckert B. Sudo K. Type 2 innate lymphoid cells disrupt bronchial epithelial barrier integrity by targeting tight junctions through IL-13 in asthmatic patients J. Allergy Clin. Immunol. 2018 141 300 310.e11 10.1016/j.jaci.2017.02.038 28392332 · DOI
  40. [42]Lee G.R. Flavell R.A. Transgenic mice which overproduce Th2 cytokines develop spontaneous atopic dermatitis and asthma Int. Immunol. 2004 16 1155 1160 10.1093/intimm/dxh117 15226271 · DOI
  41. [43]Moyle M. Cevikbas F. Harden J.L. Guttman-Yassky E. Understanding the immune landscape in atopic dermatitis: The era of biologics and emerging therapeutic approaches Exp. Dermatol. 2019 28 756 768 10.1111/exd.13911 30825336 PMC6850480 · DOI
  42. [44]Ordovas-Montanes J. Rakoff-Nahoum S. Huang S. Riol-Blanco L. Barreiro O. von Andrian U.H. The Regulation of Immunological Processes by Peripheral Neurons in Homeostasis and Disease Trends Immunol. 2015 36 578 604 10.1016/j.it.2015.08.007 26431937 PMC4592743 · DOI
  43. [45]Veiga-Fernandes H. Mucida D. Neuro-Immune Interactions at Barrier Surfaces Cell 2016 165 801 811 10.1016/j.cell.2016.04.041 27153494 PMC4871617 · DOI
  44. [46]Gabanyi I. Muller P.A. Feighery L. Oliveira T.Y. Costa-Pinto F.A. Mucida D. Neuro-immune Interactions Drive Tissue Programming in Intestinal Macrophages Cell 2016 164 378 391 10.1016/j.cell.2015.12.023 26777404 PMC4733406 · DOI
  45. [47]Talbot S. Abdulnour R.E. Burkett P.R. Lee S. Cronin S.J. Pascal M.A. Laedermann C. Foster S.L. Tran J.V. Lai N. Silencing Nociceptor Neurons Reduces Allergic Airway Inflammation Neuron 2015 87 341 354 10.1016/j.neuron.2015.06.007 26119026 PMC4506220 · DOI
  46. [48]Kashem S.W. Riedl M.S. Yao C. Honda C.N. Vulchanova L. Kaplan D.H. Nociceptive Sensory Fibers Drive Interleukin-23 Production from CD301b+ Dermal Dendritic Cells and Drive Protective Cutaneous Immunity Immunity 2015 43 515 526 10.1016/j.immuni.2015.08.016 26377898 PMC4607048 · DOI · Paper page
  47. [49]Bautista D.M. Wilson S.R. Hoon M.A. Why we scratch an itch: The molecules, cells and circuits of itch Nat. Neurosci. 2014 17 175 182 10.1038/nn.3619 24473265 PMC4364402 · DOI
  48. [50]Mack M.R. Kim B.S. The Itch-Scratch Cycle: A Neuroimmune Perspective Trends Immunol. 2018 39 980 991 10.1016/j.it.2018.10.001 30471983 PMC8896504 · DOI · Paper page
  49. [51]Yang T.B. Kim B.S. Pruritus in allergy and immunology J. Allergy Clin. Immunol. 2019 144 353 360 10.1016/j.jaci.2019.06.016 31395149 PMC6690370 · DOI · Paper page
  50. [52]Oetjen L.K. Mack M.R. Feng J. Whelan T.M. Niu H. Guo C.J. Chen S. Trier A.M. Xu A.Z. Tripathi S.V. Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch Cell 2017 171 217 228.e213 10.1016/j.cell.2017.08.006 28890086 PMC5658016 · DOI · Paper page
  51. [53]Beck L.A. Thaci D. Hamilton J.D. Graham N.M. Bieber T. Rocklin R. Ming J.E. Ren H. Kao R. Simpson E. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis N. Engl. J. Med. 2014 371 130 139 10.1056/NEJMoa1314768 25006719 · DOI
  52. [54]Bissonnette R. Papp K.A. Poulin Y. Gooderham M. Raman M. Mallbris L. Wang C. Purohit V. Mamolo C. Papacharalambous J. Topical tofacitinib for atopic dermatitis: A phase IIa randomized trial Br. J. Dermatol. 2016 175 902 911 10.1111/bjd.14871 27423107 · DOI
  53. [55]Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis Allergy 2020 75 54 62 10.1111/all.13954 31230370 · DOI · Paper page
  54. [56]Tsoi L.C. Rodriguez E. Degenhardt F. Baurecht H. Wehkamp U. Volks N. Szymczak S. Swindell W.R. Sarkar M.K. Raja K. Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis J. Investig. Dermatol. 2019 139 1480 1489 10.1016/j.jid.2018.12.018 30641038 PMC6711380 · DOI · Paper page
  55. [57]Czarnowicki T. Gonzalez J. Shemer A. Malajian D. Xu H. Zheng X. Khattri S. Gilleaudeau P. Sullivan-Whalen M. Suarez-Farinas M. Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population J. Allergy Clin. Immunol. 2015 136 104 115.e7 10.1016/j.jaci.2015.01.020 25748064 · DOI
  56. [58]Campion M. Smith L. Gatault S. Metais C. Buddenkotte J. Steinhoff M. Interleukin-4 and interleukin-13 evoke scratching behaviour in mice Exp. Dermatol. 2019 28 1501 1504 10.1111/exd.14034 31505056 · DOI
  57. [59]Dillon S.R. Sprecher C. Hammond A. Bilsborough J. Rosenfeld-Franklin M. Presnell S.R. Haugen H.S. Maurer M. Harder B. Johnston J. Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice Nat. Immunol. 2004 5 752 760 10.1038/ni1084 15184896 · DOI
  58. [60]Kato A. Fujii E. Watanabe T. Takashima Y. Matsushita H. Furuhashi T. Morita A. Distribution of IL-31 and its receptor expressing cells in skin of atopic dermatitis J. Dermatol. Sci. 2014 74 229 235 10.1016/j.jdermsci.2014.02.009 24667097 · DOI
  59. [61]Cevikbas F. Wang X. Akiyama T. Kempkes C. Savinko T. Antal A. Kukova G. Buhl T. Ikoma A. Buddenkotte J. A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1 J. Allergy Clin. Immunol. 2014 133 448 460 10.1016/j.jaci.2013.10.048 24373353 PMC3960328 · DOI
  60. [62]Feld M. Garcia R. Buddenkotte J. Katayama S. Lewis K. Muirhead G. Hevezi P. Plesser K. Schrumpf H. Krjutskov K. The pruritus- and TH2-associated cytokine IL-31 promotes growth of sensory nerves J. Allergy Clin. Immunol. 2016 138 500 508.e24 10.1016/j.jaci.2016.02.020 27212086 · DOI
  61. [63]Furue M. Ulzii D. Vu Y.H. Tsuji G. Kido-Nakahara M. Nakahara T. Pathogenesis of Atopic Dermatitis: Current Paradigm Iran. J. Immunol. 2019 16 97 107 10.22034/IJI.2019.80253 31182684 · DOI
  62. [64]Sonkoly E. Muller A. Lauerma A.I. Pivarcsi A. Soto H. Kemeny L. Alenius H. Dieu-Nosjean M.C. Meller S. Rieker J. IL-31: A new link between T cells and pruritus in atopic skin inflammation J. Allergy Clin. Immunol. 2006 117 411 417 10.1016/j.jaci.2005.10.033 16461142 · DOI
  63. [65]Lerner E.A. Is the Nervous System More Important Than the Immune System in Itch and Atopic Dermatitis? J. Investig. Dermatol. Symp. Proc. 2018 19 S94 10.1016/j.jisp.2018.10.002 30471764 · DOI
  64. [66]Tominaga M. Takamori K. Itch and nerve fibers with special reference to atopic dermatitis: Therapeutic implications J. Dermatol. 2014 41 205 212 10.1111/1346-8138.12317 24628070 · DOI
  65. [67]Cevikbas F. Steinhoff A. Homey B. Steinhoff M. Neuroimmune interactions in allergic skin diseases Curr. Opin. Allergy Clin. Immunol. 2007 7 365 373 10.1097/ACI.0b013e3282a644d2 17873574 · DOI
  66. [68]Datsi A. Steinhoff M. Ahmad F. Alam M. Buddenkotte J. Interleukin-31: The “itchy” cytokine in inflammation and therapy Allergy 2021 76 2982 2997 10.1111/all.14791 33629401 · DOI
  67. [70]Chan B.C.L. Lam C.W.K. Tam L.S. Wong C.K. IL33: Roles in Allergic Inflammation and Therapeutic Perspectives Front. Immunol. 2019 10 364 10.3389/fimmu.2019.00364 30886621 PMC6409346 · DOI
  68. [71]Voisin T. Bouvier A. Chiu I.M. Neuro-immune interactions in allergic diseases: Novel targets for therapeutics Int. Immunol. 2017 29 247 261 10.1093/intimm/dxx040 28814067 PMC5890890 · DOI
  69. [72]Cherry W.B. Yoon J. Bartemes K.R. Iijima K. Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils J. Allergy Clin. Immunol. 2008 121 1484 1490 10.1016/j.jaci.2008.04.005 18539196 PMC2821937 · DOI
  70. [73]Mitchell P.D. Salter B.M. Oliveria J.P. El-Gammal A. Tworek D. Smith S.G. Sehmi R. Gauvreau G.M. PM O.A.B. IL-33 and Its Receptor ST2 after Inhaled Allergen Challenge in Allergic Asthmatics Int. Arch. Allergy Immunol. 2018 176 133 142 10.1159/000488015 29694974 · DOI
  71. [74]Rak G.D. Osborne L.C. Siracusa M.C. Kim B.S. Wang K. Bayat A. Artis D. Volk S.W. IL-33-Dependent Group 2 Innate Lymphoid Cells Promote Cutaneous Wound Healing J. Investig. Dermatol. 2016 136 487 496 10.1038/JID.2015.406 26802241 PMC4731037 · DOI
  72. [75]Wallrapp A. Burkett P.R. Riesenfeld S.J. Kim S.J. Christian E. Abdulnour R.E. Thakore P.I. Schnell A. Lambden C. Herbst R.H. Calcitonin Gene-Related Peptide Negatively Regulates Alarmin-Driven Type 2 Innate Lymphoid Cell Responses Immunity 2019 51 709 723.e6 10.1016/j.immuni.2019.09.005 31604686 PMC7076585 · DOI
  73. [76]Hayashi H. Kawakita A. Okazaki S. Murai H. Yasutomi M. Ohshima Y. IL-33 enhanced the proliferation and constitutive production of IL-13 and IL-5 by fibrocytes BioMed Res. Int. 2014 2014 738625 10.1155/2014/738625 24822215 PMC4005215 · DOI
  74. [77]Petra A.I. Tsilioni I. Taracanova A. Katsarou-Katsari A. Theoharides T.C. Interleukin 33 and interleukin 4 regulate interleukin 31 gene expression and secretion from human laboratory of allergic diseases 2 mast cells stimulated by substance P and/or immunoglobulin E Allergy Asthma Proc. 2018 39 153 160 10.2500/aap.2018.38.4105 29490771 PMC5827155 · DOI
  75. [78]Liu B. Tai Y. Achanta S. Kaelberer M.M. Caceres A.I. Shao X. Fang J. Jordt S.E. IL-33/ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy Proc. Natl. Acad. Sci. USA 2016 113 E7572 E7579 10.1073/pnas.1606608113 27821781 PMC5127381 · DOI
  76. [79]Moniaga C.S. Jeong S.K. Egawa G. Nakajima S. Hara-Chikuma M. Jeon J.E. Lee S.H. Hibino T. Miyachi Y. Kabashima K. Protease activity enhances production of thymic stromal lymphopoietin and basophil accumulation in flaky tail mice Am. J. Pathol. 2013 182 841 851 10.1016/j.ajpath.2012.11.039 23333753 · DOI
  77. [80]Ziegler S.F. Roan F. Bell B.D. Stoklasek T.A. Kitajima M. Han H. The biology of thymic stromal lymphopoietin (TSLP) Adv. Pharmacol. 2013 66 129 155 10.1016/B978-0-12-404717-4.00004-4 23433457 PMC4169878 · DOI
  78. [81]Soumelis V. Reche P.A. Kanzler H. Yuan W. Edward G. Homey B. Gilliet M. Ho S. Antonenko S. Lauerma A. Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP Nat. Immunol. 2002 3 673 680 10.1038/ni805 12055625 · DOI
  79. [82]Wilson S.R. The L. Batia L.M. Beattie K. Katibah G.E. McClain S.P. Pellegrino M. Estandian D.M. Bautista D.M. The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch Cell 2013 155 285 295 10.1016/j.cell.2013.08.057 24094650 PMC4041105 · DOI
  80. [83]Snast I. Reiter O. Hodak E. Friedland R. Mimouni D. Leshem Y.A. Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis Am. J. Clin. Dermatol. 2018 19 145 165 10.1007/s40257-017-0324-7 29098604 · DOI
  81. [84]Paller A.S. Bansal A. Simpson E.L. Boguniewicz M. Blauvelt A. Siegfried E.C. Guttman-Yassky E. Hultsch T. Chen Z. Mina-Osorio P. Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial Am. J. Clin. Dermatol. 2020 21 119 131 10.1007/s40257-019-00478-y 31823222 PMC6989562 · DOI
  82. [86]Deleuran M. Thaci D. Beck L.A. de Bruin-Weller M. Blauvelt A. Forman S. Bissonnette R. Reich K. Soong W. Hussain I. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study J. Am. Acad. Dermatol. 2020 82 377 388 10.1016/j.jaad.2019.07.074 31374300 · DOI · Paper page
  83. [88]Silverberg J.I. Toth D. Bieber T. Alexis A.F. Elewski B.E. Pink A.E. Hijnen D. Jensen T.N. Bang B. Olsen C.K. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: Results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial Br. J. Dermatol. 2021 184 450 463 10.1111/bjd.19573 33000503 PMC7986183 · DOI
  84. [90]Kabashima K. Matsumura T. Komazaki H. Kawashima M. Nemolizumab J.P.S.G. Trial of Nemolizumab and Topical Agents for Atopic Dermatitis with Pruritus N. Engl. J. Med. 2020 383 141 150 10.1056/NEJMoa1917006 32640132 · DOI · Paper page
  85. [91]Nemoto O. Furue M. Nakagawa H. Shiramoto M. Hanada R. Matsuki S. Imayama S. Kato M. Hasebe I. Taira K. The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-controlled study Br. J. Dermatol. 2016 174 296 304 10.1111/bjd.14207 26409172 · DOI
  86. [93]Simpson E.L. Lacour J.P. Spelman L. Galimberti R. Eichenfield L.F. Bissonnette R. King B.A. Thyssen J.P. Silverberg J.I. Bieber T. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: Results from two randomized monotherapy phase III trials Br. J. Dermatol. 2020 183 242 255 10.1111/bjd.18898 31995838 · DOI · Paper page
  87. [94]Reich K. Kabashima K. Peris K. Silverberg J.I. Eichenfield L.F. Bieber T. Kaszuba A. Kolodsick J. Yang F.E. Gamalo M. Efficacy and Safety of Baricitinib Combined with Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial JAMA Dermatol. 2020 156 1333 1343 10.1001/jamadermatol.2020.3260 33001140 PMC7527941 · DOI
  88. [95]Nakagawa H. Nemoto O. Igarashi A. Saeki H. Kaino H. Nagata T. Delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with moderate to severe atopic dermatitis: A phase 3, randomized, double-blind, vehicle-controlled study and an open-label, long-term extension study J. Am. Acad. Dermatol. 2020 82 823 831 10.1016/j.jaad.2019.12.015 32029304 · DOI · Paper page
  89. [96]Nakagawa H. Nemoto O. Igarashi A. Saeki H. Murata R. Kaino H. Nagata T. Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis J. Dermatol. 2020 47 114 120 10.1111/1346-8138.15173 31820485 PMC7028108 · DOI · Paper page
  90. [97]Silverberg J.I. Simpson E.L. Thyssen J.P. Gooderham M. Chan G. Feeney C. Biswas P. Valdez H. DiBonaventura M. Nduaka C. Efficacy and Safety of Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial JAMA Dermatol. 2020 156 863 873 10.1001/jamadermatol.2020.1406 32492087 PMC7271424 · DOI
  91. [99]Guttman-Yassky E. Thaci D. Pangan A.L. Hong H.C. Papp K.A. Reich K. Beck L.A. Mohamed M.F. Othman A.A. Anderson J.K. Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial J. Allergy Clin. Immunol. 2020 145 877 884 10.1016/j.jaci.2019.11.025 31786154 · DOI
  92. [100]Silverberg J.I. de Bruin-Weller M. Bieber T. Soong W. Kabashima K. Costanzo A. Rosmarin D. Lynde C. Liu J. Gamelli A. Upadacitinib plus topical corticosteroids in atopic dermatitis: Week-52 AD Up study results J. Allergy Clin. Immunol. 2021 10.1016/j.jaci.2021.07.036 34403658 · DOI
  93. [101]Reich K. Teixeira H.D. de Bruin-Weller M. Bieber T. Soong W. Kabashima K. Werfel T. Zeng J. Huang X. Hu X. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): Results from a randomised, double-blind, placebo-controlled, phase 3 trial Lancet 2021 397 2169 2181 10.1016/S0140-6736(21)00589-4 34023009 · DOI · Paper page
  94. [102]Paller A.S. Tom W.L. Lebwohl M.G. Blumenthal R.L. Boguniewicz M. Call R.S. Eichenfield L.F. Forsha D.W. Rees W.C. Simpson E.L. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults J. Am. Acad. Dermatol. 2016 75 494 503.e6 10.1016/j.jaad.2016.05.046 27417017 · DOI
  95. [103]Yosipovitch G. Gold L.F. Lebwohl M.G. Silverberg J.I. Tallman A.M. Zane L.T. Early Relief of Pruritus in Atopic Dermatitis with Crisaborole Ointment, A Non-steroidal, Phosphodiesterase 4 Inhibitor Acta Derm.-Venereol. 2018 98 484 489 10.2340/00015555-2893 29363715 · DOI
  96. [104]Bissonnette R. Pavel A.B. Diaz A. Werth J.L. Zang C. Vranic I. Purohit V.S. Zielinski M.A. Vlahos B. Estrada Y.D. Crisaborole and atopic dermatitis skin biomarkers: An intrapatient randomized trial J. Allergy Clin. Immunol. 2019 144 1274 1289 10.1016/j.jaci.2019.06.047 31419544 · DOI
  97. [105]Simpson E.L. Parnes J.R. She D. Crouch S. Rees W. Mo M. van der Merwe R. Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial J. Am. Acad. Dermatol. 2019 80 1013 1021 10.1016/j.jaad.2018.11.059 30550828 · DOI · Paper page
  98. [106]Chen Y.L. Gutowska-Owsiak D. Hardman C.S. Westmoreland M. MacKenzie T. Cifuentes L. Waithe D. Lloyd-Lavery A. Marquette A. Londei M. Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis Sci. Transl. Med. 2019 11 eaax2945 10.1126/scitranslmed.aax2945 31645451 · DOI · Paper page
  99. [107]Cabanillas B. Brehler A.C. Novak N. Atopic dermatitis phenotypes and the need for personalized medicine Curr. Opin. Allergy Clin. Immunol. 2017 17 309 315 10.1097/ACI.0000000000000376 28582322 PMC5515628 · DOI
  100. [108]Hamilton J.D. Suarez-Farinas M. Dhingra N. Cardinale I. Li X. Kostic A. Ming J.E. Radin A.R. Krueger J.G. Graham N. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis J. Allergy Clin. Immunol. 2014 134 1293 1300 10.1016/j.jaci.2014.10.013 25482871 · DOI
  101. [109]Iannone M. Tonini G. Janowska A. Dini V. Romanelli M. Definition of treatment goals in terms of clinician-reported disease severity and patient-reported outcomes in moderate-to-severe adult atopic dermatitis: A systematic review Curr. Med. Res. Opin. 2021 37 1295 1301 10.1080/03007995.2021.1933929 34027753 · DOI
  102. [110]Ariens L.F.M. van der Schaft J. Bakker D.S. Balak D. Romeijn M.L.E. Kouwenhoven T. Kamsteeg M. Giovannone B. Drylewicz J. van Amerongen C.C.A. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry Allergy 2020 75 116 126 10.1111/all.14080 31593343 · DOI
  103. [111]Abraham S. Haufe E. Harder I. Heratizadeh A. Kleinheinz A. Wollenberg A. Weisshaar E. Augustin M. Wiemers F. Zink A. Implementation of dupilumab in routine care of atopic eczema: Results from the German national registry TREATgermany Br. J. Dermatol. 2020 183 382 384 10.1111/bjd.18958 32068242 · DOI · Paper page
  104. [113]Wollenberg A. Beck L.A. Blauvelt A. Simpson E.L. Chen Z. Chen Q. Shumel B. Khokhar F.A. Hultsch T. Rizova E. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: Results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS) Br. J. Dermatol. 2020 182 1120 1135 10.1111/bjd.18434 31407311 PMC7317598 · DOI
  105. [114]Mack M.R. Brestoff J.R. Berrien-Elliott M.M. Trier A.M. Yang T.B. McCullen M. Collins P.L. Niu H. Bodet N.D. Wagner J.A. Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis Sci. Transl. Med. 2020 12 eaay1005 10.1126/scitranslmed.aay1005 32102931 PMC7433875 · DOI
  106. [116]Kabashima K. Irie H. Interleukin-31 as a Clinical Target for Pruritus Treatment Front. Med. 2021 8 638325 10.3389/fmed.2021.638325 33644103 PMC7906974 · DOI
  107. [117]Damsky W. King B.A. JAK inhibitors in dermatology: The promise of a new drug class J. Am. Acad. Dermatol. 2017 76 736 744 10.1016/j.jaad.2016.12.005 28139263 PMC6035868 · DOI
  108. [118]Deleanu D. Nedelea I. Biological therapies for atopic dermatitis: An update Exp. Ther. Med. 2019 17 1061 1067 10.3892/etm.2018.6989 30679974 PMC6327672 · DOI
  109. [119]Schwartz D.M. Kanno Y. Villarino A. Ward M. Gadina M. O’Shea J.J. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases Nat. Rev. Drug Discov. 2017 17 78 10.1038/nrd.2017.267 PMC6168198 29282366 · DOI
  110. [120]Tanimoto A. Ogawa Y. Oki C. Kimoto Y. Nozawa K. Amano W. Noji S. Shiozaki M. Matsuo A. Shinozaki Y. Pharmacological properties of JTE-052: A novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo Inflamm. Res. Off. J. Eur. Histamine Res. Soc. 2015 64 41 51 10.1007/s00011-014-0782-9 PMC4286029 25387665 · DOI · Paper page
  111. [121]Gauvreau G.M. O’Byrne P.M. Boulet L.P. Wang Y. Cockcroft D. Bigler J. FitzGerald J.M. Boedigheimer M. Davis B.E. Dias C. Effects of an anti-TSLP antibody on allergen-induced asthmatic responses N. Engl. J. Med. 2014 370 2102 2110 10.1056/NEJMoa1402895 24846652 · DOI
  112. [122]Corren J. Parnes J.R. Wang L. Mo M. Roseti S.L. Griffiths J.M. van der Merwe R. Tezepelumab in Adults with Uncontrolled Asthma N. Engl. J. Med. 2017 377 936 946 10.1056/NEJMoa1704064 28877011 · DOI
  113. [123]Lei Y. Boinapally V. Zoltowska A. Adner M. Hellman L. Nilsson G. Vaccination against IL-33 Inhibits Airway Hyperresponsiveness and Inflammation in a House Dust Mite Model of Asthma PLoS ONE 2015 10 e0133774 10.1371/journal.pone.0133774 26214807 PMC4516261 · DOI
  114. [124]Chinthrajah S. Cao S. Liu C. Lyu S.C. Sindher S.B. Long A. Sampath V. Petroni D. Londei M. Nadeau K.C. Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy JCI Insight 2019 4 e131347 10.1172/jci.insight.131347 31723064 PMC6948865 · DOI

Authors
Moniaga, C. S., Tominaga, M., & Takamori, K.
Affiliations
Juntendo University (JP)
Corresponding author
Tominaga, Mitsutoshi
ORCID
Venue
Diagnostics
Publisher
MDPI AG
Published
2021-11-12
Volume
11
Issue
11
Pages
2090
ISSN
2075-4418 (ISSN-L)
DOI
10.3390/diagnostics11112090
PMC
PMC8618746
OpenAlex
W3213057710
Cited by
28
References
126
Citations by year
2026: 5 · 2025: 4 · 2024: 4 · 2023: 9 · 2022: 6
FWCI
0.84
Type
journal article
Language
en
Open access
Licence
Locations
  • Diagnostics (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Foundation of Strategic Research Projects in Private Universities from the Ministry of Education, Culture, Sports, Science, and Technology, Japan (S1311011)
  • Ministry of Health, Labour, and Welfare, (18K07396, 20H03568)
Topics
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
  • Health Sciences › Medicine › Physiology › Asthma and respiratory diseases
Keywords
atopic dermatitis, pruritus, type 2 inflammation, neuroimmune interactions, biologic therapy, targeted therapy

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review